| Table 1 InterventioAuthor, | Study design, | Intervention or Strategy | Reported Outcome Type | Kiles et al Framework | | |
|------------------------------------|---|--|--|--|--|--|
| Publication year, Country | Population description and size | | (ECHO) | Mapped Levels | | |
| Clinical Pharmacy | Practice | | | | | |
| Deidun et al., 2019, Australia | Quantitative, Retrospective review; Aboriginal and Torres Strait Islander Peoples; (n=64), one First Peoples primary healthcare service, remote location | 1. Medicines review and optimization | Clinical outcomes Humanistic outcomes | Patient Practice Community | | |
| Drovandi et al., 2022 Australia | Mixed methods, pragmatic pre and post quasi-experimental, participatory; Aboriginal and Torres Strait Islander Peoples; (n =17/104, 16%) 20 First Peoples primary healthcare services | 1. Medicines review and optimization | 1. Humanistic outcomes | Patient Practice | | |
| Duck, B., 2020, New Zealand | Quantitative, descriptive study, Maori and Pacific Islander Peoples (n=unknown), primary healthcare practices, rural | Medicines optimization Advanced Pharmacy Practice | 2. Clinical outcomes | Practice Community | | |
| Swain et al., 2015 Australia | Qualitative descriptive study, Aboriginal Health Workers; (n=14/31, 45%), 11 First Peoples primary healthcare services, urban, regional, rural, and remote | 1. Medicines review and optimization | 1. Humanistic outcomes | Patient Practice Community | | |
| Swain & Barclay, 2015 Australia | Qualitative explorative study, focus groups, thematic analysis: Aboriginal and Torres Strait Islander Peoples; $(n = 102)$ 11 First Peoples primary healthcare services, urban, regional, rural, and remote | 1. Medicines review and optimization | 1. Humanistic outcomes | Patient Practice Community | | |

| Harrop et al., 2024 Australia | Quantitative, pre-post, quasi- experimental (compared to non- First Peoples cohorts), interventional study: Aboriginal and Torres Strait Islander Peoples; (Pre n =199 vs 440, 45%, Post n = 119 vs 467, 26%) Tertiary Hospital, Cardiac Unit, Metropolitan | 1. 2. | Medicines optimization Care coordination | 1. | Clinical outcomes | 1. 2. 3. | Patient Practice Community |
|----------------------------------|---|----------------------|---|----------------|---|----------------|----------------------------------|
| Deming et al., 2018, (US) | Quantitative service evaluation; American Indian and Alaska Native Peoples; (n=31) 13 clinical sites | 1. 2. 3. 4. | Medicines review and optimization Pharmacy-led clinic Case-conferencing Telepharmacy | 1. | Clinical outcomes | 1. 2. | Patient Practice |
| Duvivier et al., 2017, US | Quantitative service evaluation; American Indian and Alaska Native Peoples (n=unknown) Indian Health Service-wide | 1. 2. | Medicines review and optimization Advanced Pharmacy Practice | 1. 2. | Clinical outcomes Humanistic outcomes | 1. 2. 3. | Patient Practice Community |
| Gallegos et al., 2022, US | Quantitative service evaluation; American Indian Peoples; (n=3500), regional and rural location | 1. 2. 3. | Medicines review and optimization Advanced Pharmacy Practice Telepharmacy | 1. 2. 3. | Economic outcomes Clinical outcomes Humanistic outcomes | 1. 2. 3. | Patient Practice Community |
| Geiger et al., 2018 US | Quantitative service evaluation; American Indian and Alaska Native Peoples; (n=1789) 11 separate IHS facilities, rural | 1. 2. 3. | Medicines review and optimization Advanced Pharmacy Practice Case-conferencing | 1. | Clinical outcomes | 1. 2. | Patient Practice |
| Martin et al., 2015 US | Quantitative service evaluation; American Indian and Alaska Native Peoples; (n=30) one First Peoples primary healthcare service, rural location | 1. 2. | Medicines review and optimization Pharmacy-led clinic | 1. 2. | Clinical outcomes Humanistic outcomes | 1. 2. 3. | Patient Practice Community |
| Moore et al., 2014 US | Quantitative service evaluation; American Indian and Alaska Native Peoples (n=4058) 7 IHS hospitals/clinics, 21 Tribal | 1. 2. 3. | Advanced Pharmacy Practice Case Management Medicines optimization | 3. | Clinical outcomes | 1. 2. 3. | Patient Practice Community |

| Lawrence et al., 2019 New Zealand | healthcare programs and 2 urban programs across 13 US states Quantitative program evaluation; Mãori and Pacific Peoples; (n=630/887, 71%) primary healthcare in a region | 1. | Medicines optimization | 1. 2. | Clinical outcomes Humanistic outcomes | 1. 2. | Patient Practice |
|--|--|----------------|--|----------|--|----------------|----------------------------------|
| O'Connell J et al., 2022 US | healthcare in a region Quantitative, retrospective longitudinal data analysis; American Indian and Alaska Native Peoples; (n=9844) adults aged 18 and older, 5 locations | 1. 2. | Medicines review and optimization Advanced Pharmacy Practice | m | Clinical outcomes SDOH were used to easure impact on clinical itcomes | 1. 2. 3. | Patient Practice Community |
| O'Connell J et al., 2021 US | Quantitative, retrospective longitudinal data analysis; American Indian and Alaska Native Peoples; (n=28,578) 15 IHS units | 1. 2. 3. | Medicines review and optimization Advanced Pharmacy Practice Case-conferencing | 1. | Clinical outcomes | 1. 2. 3. | Patient Practice Community |
| Pett et al., 2016 US | Quantitative, retrospective chart review, pre and postintervention; American Indian and Alaska Native Peoples; (n=61) one First Peoples primary healthcare service | 1. 2. | Medicines review and optimization Pharmacy-led clinic | 1. | Clinical outcomes | 1. 2. | Patient Practice |
| Rose J.L., 2007 US | Quantitative, cross-sectional study; Alaska Native and American Indian Peoples; (n=990) 12 remote sites | 1. 2. | Medicines review and optimization Telepharmacy | 1. 2. | Economic outcomes Clinical outcomes | 1. | Practice |
| Weston- Buffalohead J.M., 2007 US | Quantitative, descriptive, secondary data; American Indian Elders; (n=36) one residential care home | 1. | Medicines review and optimization | 1. | Clinical outcomes | 1. 2. 3. | Patient Practice Community |
| Hikaka et al., (39) 2021, New Zealand | Quantitative feasibility study; | 1. | Medicines review and optimization | 1. 2. | Clinical outcomes Humanistic outcomes | 1. 2. | Patient Practice |

| | Mãori Peoples; (n=17) adults aged 55 and older, community- dwelling | | | | | | |
|--|---|----|-----------------------------------|----|---------------------|----------------|----------------------------------|
| Hikaka et al., (62) 2021, New Zealand | Mixed Methods, structured interview with open ended questions post intervention; Mãori Peoples; (n=17) adults aged 55 and older, community- dwelling | 1. | Medicines review and optimization | 1. | Humanistic outcomes | 1. 2. | Patient Practice |
| Erker et al., | Mixed methods service | 1. | Medicines review and optimization | 1. | Clinical outcomes | 1. | Patient |
| 2021, Canada | evaluation; Canadian First Nations Peoples; (n=66) one First Peoples primary healthcare service | | | 2. | Humanistic outcomes | 2. | Practice |
| Rick et al., | Quantitative, controlled quasi- | 1. | Medicines optimization | 1. | Clinical outcomes | 1. | Patient |
| 2017 US | experimental study and retrospective analysis of secondary data; American Indian Peoples; (n=48) three retail sites | ۷. | Innovative partnerships | 3. | Humanistic outcomes | 2. 3. | Practice Community |
| Medicines Access | | | | | | | |
| Mitchell et al., 2020 Australia | Quantitative case study; Aboriginal and Torres Strait Islander Peoples; (n=296), one hospital location | 1. | Medication subsidy | 1. | Economic outcomes | 1. 2. 3. | Patient Practice Community |
| Trivedi et al., 2017 Australia | Quantitative observational time trend study, pre and post intervention; Aboriginal and Torres Strait Islander Peoples (n=42,651) age 15 years and older in 16 urban, regional, and remote locations | 1. | Medication subsidy | 1. | Clinical outcomes | 1. 2. | Patient Community |
| Trivedi et al., | Quantitative quasi-experimental | 1. | Medication subsidy | 1. | Economic outcomes | 1. | Patient |
| 2020 Australia | study, pre- and post- intervention, comparison group; | | | | | 2. | Community |

| Kelaher et al., 2006 Australia | Aboriginal and Torres Strait Islander Peoples; (n=1948) state-wide Mixed-method federal government program evaluation; Aboriginal and Torres Strait Islander Peoples; (n= 36%) 153 remote health services Australia-wide | 1. | Medication subsidy | 1. 2. | Economic outcomes Humanistic outcomes | 1. 2. 3. | Patient Practice Community |
|-------------------------------------|--|----|--|----------|--|----------------|----------------------------------|
| The Senate, 2011 Australia | Quantitative Federal Government report; Aboriginal and Torres Strait Islander; (n=170,000) 173 remote First Peoples primary healthcare services | 1. | Medication subsidy | 1. 2. | Economic outcomes Humanistic outcomes | 1. 2. | Patient Practice |
| dos Santos, 2015 Brazil | Quantitative, retrospective descriptive study; Native Brazilian Peoples; (n=unknown) Nation-wide, Indigenous health care system data | 1. | Rationalized access to essential medications (Quality Use of Medicines, QUM) | 1. | Economic outcomes | 1. 2. 3. | Patient Practice Community |
| Patel et al., 2015 Australia | Quantitative randomized, open label trial; Aboriginal and Torres Strait Islander Peoples; (n=315/623, 50%), primary healthcare, various sites | 1. | Innovative Drug Formulation | 1. | Clinical outcomes | | Patient Practice |
| Liu et al., 2015 Australia | Qualitative, semi-structured interviews; Aboriginal and Torres Strait Islander Peoples; (n=24/94, 26%), primary healthcare centres, various locations | 1. | Innovative Drug Formulation | 1. | Humanistic outcomes | 1. | Patient |
| Pilcher et al., 2014 New Zealand | Quantitative randomized controlled trial (RCT); | 1. | Innovative Drug Formulation | 1. | Clinical outcomes | 1. 2. | Patient Practice |

| Selak et al., 2016 New Zealand | Mãori Peoples; (n=44/303, 15%), various sites Quantitative randomized, open label trial; Mãori Peoples; (n=256/513, 50%), 54 primary healthcare centres | 1. Innovative Drug Formulation 1. Clinical outcomes | Patient Practice |
|-----------------------------------|--|---|---|
| Managing Medicine | 25 | | |
| McRae et al., 2008 Australia | Mixed methods program evaluation, questionnaire, 3- phase survey, semi structured interviews; Aboriginal Health Workers; (n=47), 10 localities | 1. Health literacy 1. Humanistic outcome | s 1. Patient 2. Practice |
| Gaspard et al., 2021 Canada | Quantitative program evaluation; Canadian First Nations Peoples; (n=4000 Elders) | 1. Health literacy 1. Humanistic outcome | s 1. Patient 2. Practice 3. Community |
| Walke et al., 2022 Australia | Mixed methods approach, questionnaire and focus groups; Aboriginal Peoples; (n=30) community-dwelling | 1. Dose administration aids 1. Humanistic outcome | s 1. Patient 2. Practice 3. Community |
| Navin et al., 2021 US | Quantitative retrospective analysis; American Indian and Alaska Native Peoples; (n=25) one IHS facility | 1. Dose administration aids 1. Clinical outcomes | Patient Practice |